How Will the Severe Acute Respiratory-Syndrome Treatment Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the severe acute respiratory-syndrome treatment market grown over the years?
The severe acute respiratory syndrome (SARS) treatment market has expanded significantly, projected to grow from $3.45 billion in 2024 to $3.97 billion in 2025 at a CAGR of 15.2%. Historical growth was driven by global outbreak responses, antiviral drug and vaccine development, and public health preparedness initiatives.
What Is the forecasted market size and growth rate for the severe acute respiratory-syndrome treatment market?
The severe acute respiratory syndrome treatment market is expected to grow rapidly, reaching $7.15 billion in 2029 with a 15.8% CAGR. Growth drivers include advancements in broad-spectrum antivirals, emerging therapeutics, and increased pandemic preparedness efforts. Trends involve RNA-targeted therapies, AI-driven drug discovery, global collaborations, and public health education initiatives.
Get your severe acute respiratory-syndrome treatment market report here!
What are the major factors driving growth in the severe acute respiratory-syndrome treatment market?
The escalating prevalence of respiratory ailments is anticipated to fuel the expansion of the market for severe acute respiratory syndrome treatment. These conditions, which affect the respiratory system responsible for breathing and gas exchange with the environment, could lead to respiratory failure if not treated. The treatment of severe acute respiratory syndrome helps relieve symptoms, prevent respiratory failure, decrease inflammation, and maintain oxygen levels. To illustrate, the National Asthma Council, an Australian non-profit organization for asthma care improvement and management, reported a rise in asthma-related deaths from 355 in 2021 to 467 in 2022. Consequently, the increasing prevalence of respiratory diseases is propelling the market for severe acute respiratory syndrome treatment. The severe acute respiratory syndrome treatment market is set to grow as a result of increasing investments in research and development. R&D investments encompass the financial and human resources allocated by organizations, governments or entities for investigations and activities aimed at discovering new knowledge. Such investments are critical in enhancing treatment options for severe acute respiratory syndromes such as SARS and COVID-19 as they lead to the creation of effective drugs, vaccines, diagnostics, and therapeutic approaches. The U.S. Department of Health and Human Services, for instance, granted more than $1.4 billion in August 2023 towards Project NextGen with the aim of supporting the development of next-generation COVID-19 vaccines and treatments. Therefore, the growth of the market for severe acute respiratory syndrome treatment is being propelled by the increase in research and development investments.
What key areas define the segmentation of the global severe acute respiratory-syndrome treatment Market?
The severe acute respiratory-syndrome treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antiviral: Nucleoside Analogs, Protease Inhibitors
3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids
4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies
5) By Other Drug Classes: Immunomodulators, Supportive Medications
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp
What are the top market players propelling the growth of the severe acute respiratory-syndrome treatment industry?
Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.
What are the key trends shaping the future of the severe acute respiratory-syndrome treatment market?
Leading firms in the severe acute respiratory syndrome therapy market are introducing cutting-edge techniques like multiplexed real-time PCR to maintain their market standing. This molecular biology technology enables the enlargement and identification of several DNA or RNA targets in one single process. For example, TransGen Biotech Co. Ltd., a producer and researcher of molecular and cellular biology products based in Beijing, launched the Trans-SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus Assay in July 2022. This new assay is a multiplexed real-time PCR assay that allows the detection and distinction between SARS CoV 2, Influenza A, Influenza B, and respiratory syncytial virus (RSV) using just one specimen. In addition, this tool proves useful in diagnosing and treating SARS, influenza, and RSV, effectively aiding treatment decision and hindering disease propagation.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13027
What regions are dominating the severe acute respiratory-syndrome treatment market growth?
North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Devices And Equipment (Therapeutic And Diagnostic) Global Market Report 2024
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024
Anesthesia And Respiratory Devices Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
